|
姓名：侯颖春 |
职称/职务： |
电话： |
传真： |
电子信箱：ychhou@snnu.edu.cn |
研究方向：肿瘤分子细胞生物学和诊治基础研究。1.肿瘤靶向分子筛选和肿瘤靶向化疗药物递送；2.肿瘤相关基因功能及信号转导；3.肿瘤生物医学信息学分析 |
办公地点：长安校区格物楼3218 |
一、个人简介
医学博士，博士后（美国国立卫生研究院），教授，博士生导师。本、硕、博分别毕业于西安医科大学、昆明医学院、第四军医大学。1986年硕士毕业后-1994年在第四军医大学基础部任讲师，从事教学和医学基础科研。1997年博士毕业后-1998年在第四军医大学西京医院任医师（副教授），进行临床教学和医疗。1998年-2006年在美国留学，分别在NIH（国立卫生研究院）、Wayne State University、VA Medical Center（退伍军人医疗中心）等单位做博士后(Postdoctoral Scholar)、博士后研究员(Postdoctoral Research Associate)和资深科学家（Senior Scientist）。2006年起至今在陕西师范老员工命科学学院任细胞生物学教授和博士生导师。多年来的研究主要集中于分子生物学、细胞生物学和免疫学领域，在国内外刊物发表研究论文100余篇，申报国家发明专利多项，合编科学专著、教材各3部。
在世界上首次提出了“Spatiotemporal Cell Biology”学科概念及其基本理论框架体系，“Triple W”学说和“信号域”（Signal Basin）学说。系统地在世界上首次提出了“Spatiotemporal Cell Biology”、“Triple W”、“Physiological Triple W”、“Pathological Triple W”、“Cell community”、“Signal basin”、 “GTP core”、“人体病毒感染后的三种免疫状态”等理论体系概念。
学术兼职和学术组织：
1. “国家科学技术奖”和“教育部科学技术奖”评审专家
2. 陕西省基因组与健康学会副理事长
3. 陕西省细胞生物学学会理事
4. 美国生物化学与分子生物学学会(ASBMB)会员
5. 美国微生物学学会(ASM)会员。
二、主要研究领域及兴趣
肿瘤分子细胞生物学和诊治基础研究。目前的主要研究兴趣集中于以下几方面：
1. 肿瘤靶向分子筛选和肿瘤靶向化疗药物递送
2. 肿瘤相关基因功能及信号转导
3. 肿瘤生物医学信息学分析
三、代表性论文
1. A Novel Navigated Doxorubicin Delivery Formulation to Breast Cancer Therapy. Materials Today Advances. 2022.
2. The GTP Core and Its Regulation in Spatiotemporal Cell Biology. Exploratory Research and Hypothesis in Medicine. 2022.
3. Three immunity statuses against viral infections in human. Exploratory Research and Hypothesis in Medicine. 2022.
4. ITGB1 Enhances the Proliferation, Survival, and Motility in Gastric Cancer Cells. Microsc Microanal. 2021.
5. LEF1 enhances the progression of colonic adenocarcinoma via remodeling the cell motility associated structures. Int. J. Mol. Sci. 2021.
6. The APEX1/miRNA-27a-5p axis plays key roles in progression, metastasis and targeted chemotherapy of gastric cancer. Int J Pharm. 599:120446. 2021.
7. Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library. Biotechnol Lett. 2021.
8. A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy. Nanoscale. 2020
9. Roles of N-terminal Annexin A2 phosphorylation sites and miR-206 in colonic adenocarcinoma. Life Sci. 2020
10. Development of a novel drug targeting delivery system for cervical cancer therapy. Nanotechnology. 2019
11. Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma viaCytoskeleton Structural Rearrangements. Microsc Microanal. 2019
12. A Detailed Protein-SELEX Protocol Allowing Visual Assessments of Individual Steps for a High Success Rate. Human Gene Therapy Methods, 2019
13. Screening and identification of a specific peptide binding to cervical cancer cells from a phage-displayed peptide library. Biotechnol Lett. 2017
14. The Effects of miR-29a and miR-101a Expression on the Myocardial Interstitial Collagen Generation in a Myocardial-infarcted Rat Model. Archival Of Medical Research. 2017
15. Challenges and Opportunities for siRNA-based Cancer Treatment. Cancer Lett. 2017
16. The Effects of miR-29a and miR-101a Expression on the Myocardial Interstitial Collagen Generation in a Myocardial-infarcted Rat Model. Archival Of Medical Research. 2017
17. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics. 2017
18. Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells. Scientific Reports. 2017
19. The further characterization of the peptide specifically binding to gastric cancer. Mol Cell Probes. 2016
20. ANXA2 Enhances the Progression of Hepatocellular Carcinoma via Remodeling the Cell Motility Associated Structures. Micron. 2016
21. Challenges and Opportunities for siRNA-based Cancer Treatment. Cancer Lett. 2017
22. A CD44 specific peptide developed by phage display for targeting gastric cancer. Biotechnology Letters. 2015
23. Screening of a specific peptide binding to esophageal squamous carcinoma cells from phage displayed peptide library. Mol Cell Probes. 2015
24. The Effects of Focal Adhesion Kinase on the Motility, Proliferation and Apoptosis of Caco2 and SMMC-7721 Cells. Medical oncology. 2015
25. The merged basins of signal transduction pathways in spatiotemporal cell biology. J Cell Physiol. 2014
26. Selection and characterization of a peptide specifically targeting to SGC-7901 from a phage display peptide library. Int J Pept Res Ther. 2014
27. Screening and identification of a specific peptide binding to hepatocellular carcinoma cells from a phage display peptide library. J Pep Sci. 2014
28. The further characterization of the specifically binding peptide to hepatocellular carcinoma. Biomedical Engineering: Applications, Basis and Communications. 2014
29. ANXA2 Regulates the Behaviors of SGC-7901 Cells. Asian Pac J Cancer Prev, 2013
30. ANXA2 remodels the microstructures of caco2 cells. Cell Mol Biol (Noisy-le-grand). 2013
31. Selection and characterization of colorectal cancer cell-specific peptides. Biotechnol Lett. 2013
32. The Novel Insights into Spatiotemporal Cell Biology and Its Schematic Frame, Triple W. J Cell Physiol. 2012
33. When, Where, Which. J Cell Physiol. 2011
34. Annexin A2 regulates the levels of plasminogen, S100A10 and fascin in L5178Y cells. Cancer Invest. 2008
35. Mechanisms of cancer chemoprevention by flavonoids. FASEB J. 2004
36. Carcinogenic heavy metals, Cr6+ and As3+, increase the affinity of nuclear lipocortin I heterotetramer for damaged DNAs. The Toxicologist. 2004
37. Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates. J. Immunol. 2003
38. Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx. FEMS Immunol. Med. Mic. 2003
39. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect. Immun. 2002
40. A new intra-NALT route slicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine. 2002
四、授权专利
1. 肝癌细胞表面特异性结合的多肽（ZL201510031105.8）
2. 人卵巢癌细胞一组特异结合的多肽（ZL201610966698.1）
3. 一种脂质体及其应用（受理号：201610472830.3）
4. 乳腺癌细胞一组特异结合的多肽（ZL201610085381.7）
5. 宫颈癌细胞一组特异结合的多肽（ZL201610085382.1）
6. 食道癌细胞一组特异结合的多肽（受理号：201510789928.7）
7. 胃癌细胞一组特异多肽标志物（ZL201310213900.X）
8. 一种吸管虹吸清洗器（ZL201320303091.7）
9. 结直肠癌细胞表面特异性多肽序列（ZL201010591851.X）
10. 一种结直肠癌化疗药物（ZL200610041837.6）
11. EpCAM特异性结合的多肽及其应用（202110887565.6）
12. 一种细胞变形性测定方法及测定装置的设计及其应用（202111055449.4）
五、获奖情况
1. 消化道癌靶向多肽探针系列研究，陕西高等学校科学技术奖，一等奖，2016年（第一完成人）
2. 美国国立卫生研究院/联系性疾病研究所（NIH/NIDCD）年度优秀研究论文奖，2002年（第一完成人）
3. 美国国立卫生研究院（NIH）年度优秀研究论文奖，2003年（第一完成人）
